Citation: | Zhang Yinsheng, Peng Xingtong, Yang Tingkai, et al. Recurrence of IgA nephropathy after kidney transplantation[J]. ORGAN TRANSPLANTATION, 2022, 13(5): 583-590. doi: 10.3969/j.issn.1674-7445.2022.05.006 |
[1] |
鲁芳草, 袁红伶. IgA肾病发病机制研究进展[J]. 临床肾脏病杂志, 2022, 22(2): 166-171. DOI: 10.3969/j.issn.1671-2390.2022.02.014.
LU FC, YUAN HL. Research advances on the pathogenesis of IgA nephropathy[J]. J Clin Nephrol, 2022, 22(2): 166-171. DOI: 10.3969/j.issn.1671-2390.2022.02.014.
|
[2] |
DE SOUZA L, PRUNSTER J, CHAN D, et al. Recurrent glomerulonephritis after kidney transplantation: a practical approach[J]. Curr Opin Organ Transplant, 2021, 26(4): 360-380. DOI: 10.1097/MOT.0000000000000887.
|
[3] |
UFFING A, PÉREZ-SAÉZ MJ, JOUVE T, et al. Recurrence of IgA nephropathy after kidney transplantation in adults[J]. Clin J Am Soc Nephrol, 2021, 16(8): 1247-1255. DOI: 10.2215/CJN.00910121.
|
[4] |
WYLD ML, CHADBAN SJ. Recurrent IgA nephropathy after kidney transplantation[J]. Transplantation, 2016, 100(9): 1827-1832. DOI: 10.1097/TP.0000000000001093.
|
[5] |
PATTRAPORNPISUT P, AVILA-CASADO C, REICH HN. IgA nephropathy: core curriculum 2021[J]. Am J Kidney Dis, 2021, 78(3): 429-441. DOI: 10.1053/j.ajkd.2021.01.024.
|
[6] |
OHYAMA Y, RENFROW MB, NOVAK J, et al. Aberrantly glycosylated IgA1 in IgA nephropathy: what we know and what we don't know[J]. J Clin Med, 2021, 10(16): 3467. DOI: 10.3390/jcm10163467.
|
[7] |
BERTHELOT L, ROBERT T, VUIBLET V, et al. Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes[J]. Kidney Int, 2015, 88(4): 815-822. DOI: 10.1038/ki.2015.158.
|
[8] |
BERTHOUX F, SUZUKI H, MOHEY H, et al. Prognostic value of serum biomarkers of autoimmunity for recurrence of IgA nephropathy after kidney transplantation[J]. J Am Soc Nephrol, 2017, 28(6): 1943-1950. DOI: 10.1681/ASN.2016060670.
|
[9] |
SANCHEZ-RODRIGUEZ E, SOUTHARD CT, KIRYLUK K. GWAS-based discoveries in IgA nephropathy, membranous nephropathy, and steroid-sensitive nephrotic syndrome[J]. Clin J Am Soc Nephrol, 2021, 16(3): 458-466. DOI: 10.2215/CJN.14031119.
|
[10] |
KIRYLUK K, LI Y, SCOLARI F, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens[J]. Nat Genet, 2014, 46(11): 1187-1196. DOI: 10.1038/ng.3118.
|
[11] |
张春云, 朱红艳, 夏秋翔, 等. 供肾移植术后IgA肾病的临床病理特点与预后的关系[J]. 中华器官移植杂志, 2020, 41(2): 89-93. DOI: 10.3760/cma.j.issn.0254-1785.2020.02.007.
ZHANG CY, ZHU HY, XIA QX, et al. Clinicopathologic features and prognosis of IgA nephropathy after kidney transplantation[J]. Chin J Organ Transplant, 2020, 41(2): 89-93. DOI: 10.3760/cma.j.issn.0254-1785.2020.02.007.
|
[12] |
DAHA MR, VAN KOOTEN C. Role of complement in IgA nephropathy[J]. J Nephrol, 2016, 29(1): 1-4. DOI: 10.1007/s40620-015-0245-6.
|
[13] |
ZHANG J, CHEN GD, QIU J, et al. Graft failure of IgA nephropathy in renal allografts following living donor transplantation: predictive factor analysis of 102 biopsies[J]. BMC Nephrol, 2019, 20(1): 446. DOI: 10.1186/s12882-019-1628-z.
|
[14] |
GARNIER AS, DUVEAU A, DEMISELLE J, et al. Early post-transplant serum IgA level is associated with IgA nephropathy recurrence after kidney transplantation[J]. PLoS One, 2018, 13(4): e0196101. DOI: 10.1371/journal.pone.0196101.
|
[15] |
WU MY, CHEN CS, YIANG GT, et al. The emerging role of pathogenesis of IgA nephropathy[J]. J Clin Med, 2018, 7(8): 225. DOI: 10.3390/jcm7080225.
|
[16] |
MARTÍN-PENAGOS L, BENITO-HERNÁNDEZ A, MARTÍN J, et al. APRIL serum levels relate to recurrence of IgA nephropathy[J]. Transplantation, 2018, 102(Suppl): S10. DOI: 101097/01.tp.0000542547.90273.0b.
|
[17] |
MARTÍN-PENAGOS L, BENITO-HERNÁNDEZ A, SAN SEGUNDO D, et al. A proliferation-inducing ligand increase precedes IgA nephropathy recurrence in kidney transplant recipients[J]. Clin Transplant, 2019, 33(4): e13502. DOI: 10.1111/ctr.13502.
|
[18] |
JO HA, HAN SS, LEE S, et al. The association of tumor necrosis factor superfamily 13 with recurrence of immunoglobulin A nephropathy in living related kidney transplantation[J]. BMC Nephrol, 2019, 20(1): 33. DOI: 10.1186/s12882-019-1222-4.
|
[19] |
LEE S, KIM DJ, KIM JS, et al. Identification of urinary biomarkers for recurrence of IgA nephropathy after kidney transplantation using proteomic methods[J]. Transplantation, 2018, 102(Suppl): S580. DOI: 10.1097/01.tp.0000543458.26810.ce.
|
[20] |
MORONI G, BELINGHERI M, FRONTINI G, et al. Immunoglobulin A nephropathy. recurrence after renal transplantation[J]. Front Immunol, 2019, 10: 1332. DOI: 10.3389/fimmu.2019.01332.
|
[21] |
ORTIZ F, GELPI R, KOSKINEN P, et al. IgA nephropathy recurs early in the graft when assessed by protocol biopsy[J]. Nephrol Dial Transplant, 2012, 27(6): 2553-2558. DOI: 10.1093/ndt/gfr664.
|
[22] |
LIONAKI S, PANAGIOTELLIS K, MELEXOPOULOU C, et al. The clinical course of IgA nephropathy after kidney transplantation and its management[J]. Transplant Rev (Orlando), 2017, 31(2): 106-114. DOI: 10.1016/j.trre.2017.01.005.
|
[23] |
COSIO FG, CATTRAN DC. Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation[J]. Kidney Int, 2017, 91(2): 304-314. DOI: 10.1016/j.kint.2016.08.030.
|
[24] |
ALLEN PJ, CHADBAN SJ, CRAIG JC, et al. Recurrent glomerulonephritis after kidney transplantation: risk factors and allograft outcomes[J]. Kidney Int, 2017, 92(2): 461-469. DOI: 10.1016/j.kint.2017.03.015.
|
[25] |
杨喆, 兰平, 郑瑾, 等. 肾移植术后IgA肾病临床病理特征分析[J]. 诊断病理学杂志, 2021, 28(4): 285-289, 294. DOI: 10.3969/j.issn.1007-8096.2021.04.011.
YANG Z, LAN P, ZHENG J, et al. Clinicopathologic features of IgA nephropathy after renal transplantation[J]. Chin J Diag Pathol, 2021, 28(4): 285-289, 294. DOI: 10.3969/j.issn.1007-8096.2021.04.011.
|
[26] |
Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, ROBERTS IS, COOK HT, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility[J]. Kidney Int, 2009, 76(5): 546-556. DOI: 10.1038/ki.2009.168.
|
[27] |
MORONI G, LONGHI S, QUAGLINI S, et al. The long-term outcome of renal transplantation of IgA nephropathy and the impact of recurrence on graft survival[J]. Nephrol Dial Transplant, 2013, 28(5): 1305-1314. DOI: 10.1093/ndt/gfs472.
|
[28] |
TRIMARCHI H, BARRATT J, CATTRAN DC, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group[J]. Kidney Int, 2017, 91(5): 1014-1021. DOI: 10.1016/j.kint.2017.02.003.
|
[29] |
BARBOUR SJ, ESPINO-HERNANDEZ G, REICH HN, et al. The MEST score provides earlier risk prediction in IgA nephropathy[J]. Kidney Int, 2016, 89(1): 167-175. DOI: 10.1038/ki.2015.322.
|
[30] |
LV J, SHI S, XU D, et al. Evaluation of the Oxford classification of IgA nephropathy: a systematic review and Meta-analysis[J]. Am J Kidney Dis, 2013, 62(5): 891-899. DOI: 10.1053/j.ajkd.2013.04.021.
|
[31] |
PARK S, GO H, BAEK CH, et al. Clinical importance of the updated Oxford classification in allograft IgA nephropathy[J]. Am J Transplant, 2019, 19(10): 2855-2864. DOI: 10.1111/ajt.15400.
|
[32] |
季曙明, 倪雪峰, 谢轲楠, 等. 肾移植术后IgA肾病复发并非总是良性预后[J]. 器官移植, 2016, 7(2): 94-99. DOI: 10.3969/j.issn.1674-7445.2016.02.003.
JI SM, NI XF, XIE KN, et al. Recurrent IgA nephropathy after renal transplantation: not always a benign prognosis[J]. Organ Transplant, 2016, 7(2): 94-99. DOI: 10.3969/j.issn.1674-7445.2016.02.003.
|
[33] |
LIM WH, SHINGDE M, WONG G. Recurrent and de novo glomerulonephritis after kidney transplantation[J]. Front Immunol, 2019, 10: 1944. DOI: 10.3389/fimmu.2019.01944.
|
[34] |
AHN S, MIN SI, MIN SK, et al. Different recurrence rates between pediatric and adult renal transplant for immunoglobulin A nephropathy: predictors of posttransplant recurrence[J]. Exp Clin Transplant, 2015, 13(3): 227-232.
|
[35] |
王一喆, 王凯, 李明, 等. 肾移植术后IgA肾病复发危险因素分析[J/CD]. 实用器官移植电子杂志, 2021, 9(2): 126-130. DOI: 10.3969/j.issn.2095-5332.2021.02.009.
WANG YZ, WANG K, LI M, et al. Risk factors for recurrence of IgA nephropathy after kidney transplantation[J/CD]. Pract J Organ Transplant (Electr Vers), 2021, 9(2): 126-130. DOI: 10.3969/j.issn.2095-5332.2021.02.009.
|
[36] |
AVASARE RS, ROSENSTIEL PE, ZAKY ZS, et al. Predicting post-transplant recurrence of IgA nephropathy: the importance of crescents[J]. Am J Nephrol, 2017, 45(2): 99-106. DOI: 10.1159/000453081.
|
[37] |
FREESE P, SVALANDER C, NORDÉN G, et al. Clinical risk factors for recurrence of IgA nephropathy[J]. Clin Transplant, 1999, 13(4): 313-317. DOI: 10.1034/j.1399-0012.1999.130406.x.
|
[38] |
DI VICO MC, MESSINA M, FOP F, et al. Recurrent IgA nephropathy after renal transplantation and steroid withdrawal[J]. Clin Transplant, 2018, 32(4): e13207. DOI: 10.1111/ctr.13207.
|
[39] |
WANG AY, LAI FM, YU AW, et al. Recurrent IgA nephropathy in renal transplant allografts[J]. Am J Kidney Dis, 2001, 38(3): 588-596. DOI: 10.1053/ajkd.2001.26885.
|
[40] |
SOFUE T, INUI M, HARA T, et al. Latent IgA deposition from donor kidneys does not affect transplant prognosis, irrespective of mesangial expansion[J]. Clin Transplant, 2013, 27(Suppl 26): 14-21. DOI: 10.1111/ctr.12158.
|
[41] |
KAVANAGH CR, ZANONI F, LEAL R, et al. Clinical predictors and prognosis of recurrent IgA nephropathy in the kidney allograft[J]. Glomerular Dis, 2022, 2(1): 42-53. DOI: 10.1159/000519834.
|
[42] |
MCDONALD SP, RUSS GR. Recurrence of IgA nephropathy among renal allograft recipients from living donors is greater among those with zero HLA mismatches[J]. Transplantation, 2006, 82(6): 759-762. DOI: 10.1097/01.tp.0000230131.66971.45.
|
[43] |
ROVIN BH, ADLER SG, BARRATT J, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases[J]. Kidney Int, 2021, 100(4): 753-779. DOI: 10.1016/j.kint.2021.05.015.
|
[44] |
PARK S, BAEK CH, GO H, et al. Possible beneficial association between renin-angiotensin-aldosterone-system blockade usage and graft prognosis in allograft IgA nephropathy: a retrospective cohort study[J]. BMC Nephrol, 2019, 20(1): 354. DOI: 10.1186/s12882-019-1537-1.
|
[45] |
HIREMATH S, FERGUSSON DA, FERGUSSON N, et al. Renin-angiotensin system blockade and long-term clinical outcomes in kidney transplant recipients: a Meta-analysis of randomized controlled trials[J]. Am J Kidney Dis, 2017, 69(1): 78-86. DOI: 10.1053/j.ajkd.2016.08.018.
|
[46] |
LV J, ZHANG H, WONG MG, et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial[J]. JAMA, 2017, 318(5): 432-442. DOI: 10.1001/jama.2017.9362.
|
[47] |
NATALE P, PALMER SC, RUOSPO M, et al. Immunosuppressive agents for treating IgA nephropathy[J]. Cochrane Database Syst Rev, 2020, 3(3): CD003965. DOI: 10.1002/14651858.CD003965.pub3.
|
[48] |
HOU JH, LE WB, CHEN N, et al. Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial[J]. Am J Kidney Dis, 2017, 69(6): 788-795. DOI: 10.1053/j.ajkd.2016.11.027.
|
[49] |
LIU T, WANG Y, MAO H, et al. Efficacy and safety of immunosuppressive therapies in the treatment of high-risk IgA nephropathy: a network Meta-analysis[J]. Medicine (Baltimore), 2021, 100(8): e24541. DOI: 10.1097/MD.0000000000024541.
|
[50] |
INFANTE B, ROSSINI M, DI LORENZO A, et al. Recurrence of immunoglobulin A nephropathy after kidney transplantation: a narrative review of the incidence, risk factors, pathophysiology and management of immunosuppressive therapy[J]. Clin Kidney J, 2020, 13(5): 758-767. DOI: 10.1093/ckj/sfaa060.
|
[51] |
LEE KW, KIM KS, LEE JS, et al. Impact of induction immunosuppression on the recurrence of primary IgA nephropathy[J]. Transplant Proc, 2019, 51(5): 1491-1495. DOI: 10.1016/j.transproceed.2019.01.115.
|
[52] |
FELLSTRÖM BC, BARRATT J, COOK H, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial[J]. Lancet, 2017, 389(10084): 2117-2127. DOI: 10.1016/S0140-6736(17)30550-0.
|
[53] |
HIRANO K, MATSUZAKI K, YASUDA T, et al. Association between tonsillectomy and outcomes in patients with immunoglobulin A nephropathy[J]. JAMA Netw Open, 2019, 2(5): e194772. DOI: 10.1001/jamanetworkopen.2019.4772.
|
[54] |
KAWABE M, YAMAMOTO I, YAMAKAWA T, et al. Association between galactose-deficient IgA1 derived from the tonsils and recurrence of IgA nephropathy in patients who underwent kidney transplantation[J]. Front Immunol, 2020, 11: 2068. DOI: 10.3389/fimmu.2020.02068.
|
[55] |
HOTTA K, FUKASAWA Y, AKIMOTO M, et al. Tonsillectomy ameliorates histological damage of recurrent immunoglobulin A nephropathy after kidney transplantation[J]. Nephrology (Carlton), 2013, 18(12): 808-812. DOI: 10.1111/nep.12151.
|
[56] |
邓荣海, 李健, 张桓熙, 等. 扁桃体切除术对肾移植术后IgA肾病的治疗效果[J]. 中华医学杂志, 2020, 100(30): 2378-2382. DOI: 10.3760/cma.j.cn112137-20191120-02526.
DENG RH, LI J, ZHANG HX, et al. Therapeutic effect of tonsillectomy on IgA nephropathy after kidney transplantation[J]. Natl Med J China, 2020, 100(30): 2378-2382. DOI: 10.3760/cma.j.cn112137-20191120-02526.
|
[57] |
RIZK DV, MAILLARD N, JULIAN BA, et al. The emerging role of complement proteins as a target for therapy of IgA nephropathy[J]. Front Immunol, 2019, 10: 504. DOI: 10.3389/fimmu.2019.00504.
|
[58] |
SHARMA A, HARIHARAN S. Octreotide delaying the progression of recurrent IgA nephropathy after kidney transplantation[J]. Transplant Direct, 2019, 6(1): e518. DOI: 10.1097/TXD.0000000000000963.
|
[59] |
NOGUCHI H, TSUCHIMOTO A, UEKI K, et al. Reduced recurrence of primary IgA nephropathy in kidney transplant recipients receiving everolimus with corticosteroid: a retrospective, single-center study of 135 transplant patients[J]. Transplant Proc, 2020, 52(10): 3118-3124. DOI: 10.1016/j.transproceed.2020.05.022.
|